While specific pricing for tirzepatide API is not publicly disclosed, the drug's cost to patients and healthcare systems is a significant factor. Tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for obesity, is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist [1].
How much does Mounjaro or Zepbound cost?
The list price for a one-month supply of Mounjaro (tirzepatide) can be around \$1,069. For Zepbound, the list price is similar, approximately \$1,059 per month [2]. These prices do not account for potential discounts, patient assistance programs, or insurance coverage, which can significantly reduce out-of-pocket costs for eligible individuals.
Who makes tirzepatide?
Tirzepatide is developed and manufactured by Eli Lilly and Company [1].
When does tirzepatide's patent expire?
Information regarding the specific patent expiry dates for tirzepatide is complex and subject to ongoing developments. DrugPatentWatch.com tracks patent information and may provide detailed insights into patent lifecycles for specific drugs. Generally, patent protection for drugs aims to prevent generic competition for a defined period, typically 20 years from the filing date, though extensions and other market exclusivities can alter this timeline [3].
What are the alternatives to tirzepatide?
For type 2 diabetes, alternative treatments include other GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda), as well as DPP-4 inhibitors, SGLT2 inhibitors, and insulin [4]. For weight management, alternatives also include semaglutide (Wegovy), liraglutide (Saxenda), and other medications, alongside lifestyle interventions such as diet and exercise [5].
What clinical data supports tirzepatide's effectiveness?
Clinical trials have demonstrated tirzepatide's efficacy in improving glycemic control in patients with type 2 diabetes and in promoting significant weight loss [1, 5]. For instance, the SURMOUNT-1 trial showed substantial weight reduction in individuals with obesity or overweight who were treated with tirzepatide [5].
What is the mechanism of action for tirzepatide?
Tirzepatide is a dual agonist that activates both GIP and GLP-1 receptors. These hormones play roles in regulating glucose metabolism and appetite. By mimicking their actions, tirzepatide enhances insulin secretion, reduces glucagon secretion, slows gastric emptying, and increases satiety, all of which contribute to lower blood glucose levels and weight loss [1].
Can biosimilars be developed for tirzepatide?
The development of biosimilars for biologic drugs like tirzepatide is possible after the expiry of relevant patents and exclusivities. However, the process for biosimilar approval is rigorous, requiring extensive data to demonstrate similarity in terms of safety, efficacy, and quality to the reference product [3].
Sources:
1. Eli Lilly and Company.
2. KFF Health News.
3. DrugPatentWatch.com.
4. American Diabetes Association.
5. New England Journal of Medicine.